secwatch.observer — SEC 8-K summary
======================================

Issuer:     CalciMedica, Inc. (CALC)
CIK:        0001534133
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0000950170-25-106918
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CalciMedica Q2 net loss $6.0M ($0.40/sh); cash $18.0M; KOURAGE trial data expected early 2026
--------------------------------------------------------------------------------

- Net loss of $6.0M, or $0.40 per share, vs $4.0M ($0.36) in Q2 2024.
- Cash and investments $18.0M; expected to fund operations into mid-2026.
- R&D expenses $4.1M, G&A $2.6M; other income fell to $0.7M from $2.6M.
- Enrollment ongoing in Phase 2 KOURAGE trial for AKI with respiratory failure; 150 patients planned.
- Initial FDA meeting on Auxora for acute pancreatitis constructive; pivotal trial alignment expected end-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534133/000095017025106918/0000950170-25-106918-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534133/000095017025106918/ck0001534133-20250812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-106918

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer